Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce and labor, ESRD PPS forecast error, Medicare Physician Fee Schedule Provider Enrollment Issues, closures of dialysis facilities and concerns regarding access to care for Americans living with kidney failure
Duration: January 1, 2008
to
present
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations , Medical/Disease Research/Clinical Labs
Spending: about $13,230,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), White House Office, Office of Management & Budget (OMB), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC), Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS),, Veterans Affairs - Dept of (VA), Health & Human Services - Dept of (HHS), Treasury - Dept of
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Feb. 26.
Original Filing: 301544651.xml
Lobbying Issues
Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce and labor, ESRD PPS forecast error, Medicare Physician Fee Schedule Provider Enrollment Issues, closures of dialysis facilities and concerns regarding access to care for Americans living with kidney failure
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Medicare Payment Advisory Commission (MedPAC) White House Office Office of Management & Budget (OMB)
Lobbying Issues
Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce and labor, ESRD PPS forecast error, Medicare Physician Fee Schedule Provider Enrollment Issues, closures of dialysis facilities and concerns regarding access to care for Americans living with kidney failure
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB) White House Office
3rd Quarter, 2023
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Nov. 21, 2023.
Original Filing: 301519675.xml
Lobbying Issues
Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce and labor, ESRD PPS forecast error, Medicare Physician Fee Schedule Provider Enrollment Issues, closures of dialysis facilities and concerns regarding access to care for Americans living with kidney failure
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Medicare Payment Advisory Commission (MedPAC) White House Office Office of Management & Budget (OMB)
Lobbying Issues
Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce and labor, ESRD PPS forecast error, Medicare Physician Fee Schedule Provider Enrollment Issues, closures of dialysis facilities and concerns regarding access to care for Americans living with kidney failure
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB) White House Office
2nd Quarter, 2023
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Sept. 1, 2023.
Original Filing: 301495929.xml
Lobbying Issues
Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Medicare Payment Advisory Commission (MedPAC) White House Office Office of Management & Budget (OMB)
Lobbying Issues
Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB) White House Office
1st Quarter, 2023
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on June 1, 2023.
Original Filing: 301471915.xml
Lobbying Issues
Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Medicare Payment Advisory Commission (MedPAC) White House Office Office of Management & Budget (OMB)
Lobbying Issues
Kidney Care reimbursement issues; End Stage Renal Disease Prospective Payment System; Medicare Secondary Payer; ESRD quality programs; workforce
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB) White House Office
4th Quarter, 2022
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Feb. 23, 2023.
Original Filing: 301447099.xml
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency. Medicare sequester and PAYGO sequester, Telehealth, Restore Protections for Dialysis Patients Act. ESRD PPS and QIP, ESRD Treatment Choices Model, Medicare Advantage program rules and guidance.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Medicare Payment Advisory Commission (MedPAC)
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency. Medicare sequester and PAYGO sequester, Telehealth, Restore Protections for Dialysis Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
3rd Quarter, 2022
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Nov. 15, 2022.
Original Filing: 301422839.xml
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency. Medicare sequester and PAYGO sequester, Telehealth, Restore Protections for Dialysis Patients Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Medicare/Medicaid
2nd Quarter, 2022
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on June 2, 2022.
Original Filing: 301376089.xml
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency. Medicare sequester and PAYGO sequester, Telehealth.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Medicare/Medicaid
1st Quarter, 2022
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on June 2, 2022.
Original Filing: 301376087.xml
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency. Medicare sequester and PAYGO sequester, Telehealth.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Medicare/Medicaid
4th Quarter, 2021
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Dec. 2, 2021.
Original Filing: 301318840.xml
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency. Medicare sequester and PAYGO sequester.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency. Medicare sequester and PAYGO sequester.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
3rd Quarter, 2021
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Dec. 2, 2021.
Original Filing: 301318837.xml
Lobbying Issues
Medicare reimbursement and policy issues related to kidney disease and End Stage Renal Disease, COVID-19 public health emergency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Medicare/Medicaid
3rd Quarter, 2021
THE KIDNEY CARE COUNCIL amended a lobbying report for in-house lobbying in Q32021 on Dec. 2, 2021
Original Filing: 301318839.xml
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2021
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Dec. 2, 2021.
Original Filing: 301318838.xml
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2021
THE KIDNEY CARE COUNCIL amended a lobbying report for in-house lobbying in Q12021 on Sept. 24, 2021
Original Filing: 301295704.xml
Lobbying Issues
End Stage Renal Disease Prospective Payment System, Quality Incentive Program ESRD Treatment Choice Model. Issues related to COVID-19 public health emergency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
1st Quarter, 2021
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on June 7, 2021.
Original Filing: 301272268.xml
Lobbying Issues
ESRD PPS and QIP, ESRD Treatment Choices Model, Medicare Advantage program rules and guidance, COVID-19 policies including vaccines for patients with kidney disease
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Centers For Disease Control & Prevention (CDC) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB) Executive Office of the President (EOP)
Lobbying Issues
ESRD PPS and QIP, ESRD Treatment Choices Model, Medicare Advantage program rules and guidance, COVID-19 vaccines for patients with kidney disease
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) Centers For Disease Control & Prevention (CDC) Office of Management & Budget (OMB) Health & Human Services - Dept of (HHS)
4th Quarter, 2020
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Feb. 16, 2021.
Original Filing: 301248423.xml
Lobbying Issues
ESRD Prospective Payment System CY 2021 and Quality Incentive Program Proposed Rule; ESRD Treatment Choices Model rule; issues related to COVID public health emergency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
ESRD Prospective Payment System CY 2021 and Quality Incentive Program Proposed Rule; ESRD Treatment Choices Model proposed rule; issues related to COVID public health emergency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2020
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Nov. 20, 2020.
Original Filing: 301227183.xml
Lobbying Issues
ESRD Prospective Payment System CY 2021 and Quality Incentive Program Proposed Rule; ESRD Treatment Choices Model rule; issues related to COVID public health emergency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
ESRD Prospective Payment System CY 2021 and Quality Incentive Program Proposed Rule; ESRD Treatment Choices Model proposed rule; issues related to COVID public health emergency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2020
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Sept. 1, 2020.
Original Filing: 301206084.xml
Lobbying Issues
ESRD Prospective Payment System CY 2021 and Quality Incentive Program Proposed Rule; ESRD Treatment Choices Model proposed rule; issues related to COVID public health emergency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
ESRD Prospective Payment System CY 2021 and Quality Incentive Program Proposed Rule; ESRD Treatment Choices Model proposed rule; issues related to COVID public health emergency
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2020
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on June 8, 2020.
Original Filing: 301184297.xml
Lobbying Issues
ESRD Prospective Payment System CY 2020 and Quality Incentive Program PY 2020-23 Proposed Rule; ESRD Five Star Program; charitable premium assistance, ESRD Treatment Choices Model proposed rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
4th Quarter, 2019
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Feb. 20, 2020.
Original Filing: 301142083.xml
Lobbying Issues
ESRD Prospective Payment System CY 2020 and Quality Incentive Program PY 2020-23 Proposed Rule; ESRD Five Star Program; charitable premium assistance, ESRD Treatment Choices Model proposed rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
3rd Quarter, 2019
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Nov. 6, 2019.
Original Filing: 301080953.xml
Lobbying Issues
ESRD Prospective Payment System CY 2020 and Quality Incentive Program PY 2020-23 Proposed Rule; ESRD Five Star Program; charitable premium assistance, ESRD Treatment Choices Model proposed rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
2nd Quarter, 2019
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Sept. 4, 2019.
Original Filing: 301061852.xml
Lobbying Issues
ESRD Prospective Payment System CY 2020 and Quality Incentive Program PY 2020-23 Proposed Rule; ESRD Five Star Program; charitable premium assistance
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
1st Quarter, 2019
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on May 22, 2019.
Original Filing: 301041171.xml
Lobbying Issues
ESRD Prospective Payment System CY 2020 and Quality Incentive Program PY 2020-23 Proposed Rule; ESRD Five Star Program; charitable premium assistance
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
4th Quarter, 2018
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Dec. 13, 2018.
Original Filing: 301001431.xml
Lobbying Issues
CMS Proposed Updates to Policies and Payment Rates for End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (CMS 1674-P);
Issues related to survey and certification of dialysis facilities under sub-regulatory guidance issued by the CMS Centers for Clinical Standards and Quality, Survey and Certification Group;
Issues related to charitable premium assistance for individuals with ESRD;
H.R. 3976, The Protecting Access to Marketplace Insurance Act of 2017;
H.R. 5942 PATIENTs Act (114th Congress);
S. 870, CHRONIC Act of 2017;
H.R. 3178, Medicare Part B Improvement Act (includes H.R. 3166, dialysis facility accreditation legislation) of 2017;
H.R. 2644, CKD Improvement in Research and Treatment Act of 2017;
Issues related to End Stage Renal Disease (ESRD) program and Chronic Kidney Disease (CKD);
H.R. 2644/S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017;
Issues related to opioid policies and offsets - H.R. 6, SUBSTANCE USE-DISORDER PREVENTION THAT PROMOTES OPIOID RECOVERY AND TREATMENT (SUPPORT) FOR PATIENTS AND COMMUNITIES ACTS. 3120: Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018 S.2680 - Opioid Crisis Response Act of 2018;
ESRD Prospective Payment System CY 2018 and Quality Incentive Program PY 2019-21 Proposed Rule;
ESRD Five Star Program; charitable premium assistance;
Skilled Nursing Facility Proposed rule (issues related to hospital discharge information)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
CMS Proposed Updates to Policies and Payment Rates for End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (CMS 1674-P)
Issues related to survey and certification of dialysis facilities under sub-regulatory guidance issued by the CMS Centers for Clinical Standards and Quality
Issues related to charitable premium assistance for individuals with ESRD
H.R. 3976, The Protecting Access to Marketplace Insurance Act of 2017
H.R. 5942 PATIENTs Act (114th Congress)
S. 870, CHRONIC Act of 2017
H.R. 3178, Medicare Part B Improvement Act (includes H.R. 3166, dialysis facility accreditation legislation) of 2017
H.R. 2644, CKD Improvement in Research and Treatment Act of 2017
ESRD Prospective Payment System CY 2018 and Quality Incentive Program PY 2019-21 Proposed Rule
ESRD Five Star Program
charitable premium assistance
Issues related to End Stage Renal Disease (ESRD) program and Chronic Kidney Disease (CKD)
S.870, CHRONIC Care Act of 2017
SNP reauthorization
H.R. 2644/S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017
Medicare extenders package
H.R. 3178, Medicare Part B Improvement Act of 2017
Issues related to healthcare discussions/offsets for budget deal and healthcare extender policies
H.R. 1892 / PL 115-123, Bipartisan Budget Act of 2018
H.R. 1625 / PL 115-141, Omnibus/Consolidated Appropriations Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2018
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Dec. 13, 2018.
Original Filing: 301001430.xml
Lobbying Issues
CMS Proposed Updates to Policies and Payment Rates for End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (CMS 1674-P);
Issues related to survey and certification of dialysis facilities under sub-regulatory guidance issued by the CMS Centers for Clinical Standards and Quality, Survey and Certification Group;
Issues related to charitable premium assistance for individuals with ESRD;
H.R. 3976, The Protecting Access to Marketplace Insurance Act of 2017;
H.R. 5942 PATIENTs Act (114th Congress);
S. 870, CHRONIC Act of 2017;
H.R. 3178, Medicare Part B Improvement Act (includes H.R. 3166, dialysis facility accreditation legislation) of 2017;
H.R. 2644, CKD Improvement in Research and Treatment Act of 2017;
Issues related to End Stage Renal Disease (ESRD) program and Chronic Kidney Disease (CKD);
H.R. 2644/S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017;
Issues related to opioid policies and offsets - H.R. 6, SUBSTANCE USE-DISORDER PREVENTION THAT PROMOTES OPIOID RECOVERY AND TREATMENT (SUPPORT) FOR PATIENTS AND COMMUNITIES ACTS. 3120: Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018 S.2680 - Opioid Crisis Response Act of 2018;
ESRD Prospective Payment System CY 2018 and Quality Incentive Program PY 2019-21 Proposed Rule;
ESRD Five Star Program; charitable premium assistance;
Skilled Nursing Facility Proposed rule (issues related to hospital discharge information)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
CMS Proposed Updates to Policies and Payment Rates for End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (CMS 1674-P)
Issues related to survey and certification of dialysis facilities under sub-regulatory guidance issued by the CMS Centers for Clinical Standards and Quality
Issues related to charitable premium assistance for individuals with ESRD
H.R. 3976, The Protecting Access to Marketplace Insurance Act of 2017
H.R. 5942 PATIENTs Act (114th Congress)
S. 870, CHRONIC Act of 2017
H.R. 3178, Medicare Part B Improvement Act (includes H.R. 3166, dialysis facility accreditation legislation) of 2017
H.R. 2644, CKD Improvement in Research and Treatment Act of 2017
ESRD Prospective Payment System CY 2018 and Quality Incentive Program PY 2019-21 Proposed Rule
ESRD Five Star Program
charitable premium assistance
Issues related to End Stage Renal Disease (ESRD) program and Chronic Kidney Disease (CKD)
S.870, CHRONIC Care Act of 2017
SNP reauthorization
H.R. 2644/S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017
Medicare extenders package
H.R. 3178, Medicare Part B Improvement Act of 2017
Issues related to healthcare discussions/offsets for budget deal and healthcare extender policies
H.R. 1892 / PL 115-123, Bipartisan Budget Act of 2018
H.R. 1625 / PL 115-141, Omnibus/Consolidated Appropriations Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2018
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Aug. 10, 2018.
Original Filing: 300980556.xml
Lobbying Issues
CMS Proposed Updates to Policies and Payment Rates for End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (CMS 1674-P);
Issues related to survey and certification of dialysis facilities under sub-regulatory guidance issued by the CMS Centers for Clinical Standards and Quality, Survey and Certification Group;
Issues related to charitable premium assistance for individuals with ESRD;
H.R. 3976, The Protecting Access to Marketplace Insurance Act of 2017;
H.R. 5942 PATIENTs Act (114th Congress);
S. 870, CHRONIC Act of 2017;
H.R. 3178, Medicare Part B Improvement Act (includes H.R. 3166, dialysis facility accreditation legislation) of 2017;
H.R. 2644, CKD Improvement in Research and Treatment Act of 2017;
Issues related to End Stage Renal Disease (ESRD) program and Chronic Kidney Disease (CKD);
H.R. 2644/S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017;
Issues related to opioid policies and offsets - H.R. 6, SUBSTANCE USE-DISORDER PREVENTION THAT PROMOTES OPIOID RECOVERY AND TREATMENT (SUPPORT) FOR PATIENTS AND COMMUNITIES ACTS. 3120: Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018 S.2680 - Opioid Crisis Response Act of 2018;
ESRD Prospective Payment System CY 2018 and Quality Incentive Program PY 2019-21 Proposed Rule;
ESRD Five Star Program; charitable premium assistance;
Skilled Nursing Facility Proposed rule (issues related to hospital discharge information)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
CMS Proposed Updates to Policies and Payment Rates for End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (CMS 1674-P)
Issues related to survey and certification of dialysis facilities under sub-regulatory guidance issued by the CMS Centers for Clinical Standards and Quality
Issues related to charitable premium assistance for individuals with ESRD
H.R. 3976, The Protecting Access to Marketplace Insurance Act of 2017
H.R. 5942 PATIENTs Act (114th Congress)
S. 870, CHRONIC Act of 2017
H.R. 3178, Medicare Part B Improvement Act (includes H.R. 3166, dialysis facility accreditation legislation) of 2017
H.R. 2644, CKD Improvement in Research and Treatment Act of 2017
ESRD Prospective Payment System CY 2018 and Quality Incentive Program PY 2019-21 Proposed Rule
ESRD Five Star Program
charitable premium assistance
Issues related to End Stage Renal Disease (ESRD) program and Chronic Kidney Disease (CKD)
S.870, CHRONIC Care Act of 2017
SNP reauthorization
H.R. 2644/S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017
Medicare extenders package
H.R. 3178, Medicare Part B Improvement Act of 2017
Issues related to healthcare discussions/offsets for budget deal and healthcare extender policies
H.R. 1892 / PL 115-123, Bipartisan Budget Act of 2018
H.R. 1625 / PL 115-141, Omnibus/Consolidated Appropriations Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2018
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on June 1, 2018.
Original Filing: 300960970.xml
Lobbying Issues
CMS Proposed Updates to Policies and Payment Rates for End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (CMS 1674-P)
Issues related to survey and certification of dialysis facilities under sub-regulatory guidance issued by the CMS Centers for Clinical Standards and Quality
Issues related to charitable premium assistance for individuals with ESRD
H.R. 3976, The Protecting Access to Marketplace Insurance Act of 2017
H.R. 5942 PATIENTs Act (114th Congress)
S. 870, CHRONIC Act of 2017
H.R. 3178, Medicare Part B Improvement Act (includes H.R. 3166, dialysis facility accreditation legislation) of 2017
H.R. 2644, CKD Improvement in Research and Treatment Act of 2017
ESRD Prospective Payment System CY 2018 and Quality Incentive Program PY 2019-21 Proposed Rule
ESRD Five Star Program
charitable premium assistance
Issues related to End Stage Renal Disease (ESRD) program and Chronic Kidney Disease (CKD)
S.870, CHRONIC Care Act of 2017
SNP reauthorization
H.R. 2644/S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017
Medicare extenders package
H.R. 3178, Medicare Part B Improvement Act of 2017
Issues related to healthcare discussions/offsets for budget deal and healthcare extender policies
H.R. 1892 / PL 115-123, Bipartisan Budget Act of 2018
H.R. 1625 / PL 115-141, Omnibus/Consolidated Appropriations Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
CMS Proposed Updates to Policies and Payment Rates for End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (CMS 1674-P)
Issues related to survey and certification of dialysis facilities under sub-regulatory guidance issued by the CMS Centers for Clinical Standards and Quality
Issues related to charitable premium assistance for individuals with ESRD
H.R. 3976, The Protecting Access to Marketplace Insurance Act of 2017
H.R. 5942 PATIENTs Act (114th Congress)
S. 870, CHRONIC Act of 2017
H.R. 3178, Medicare Part B Improvement Act (includes H.R. 3166, dialysis facility accreditation legislation) of 2017
H.R. 2644, CKD Improvement in Research and Treatment Act of 2017
ESRD Prospective Payment System CY 2018 and Quality Incentive Program PY 2019-21 Proposed Rule
ESRD Five Star Program
charitable premium assistance
Issues related to End Stage Renal Disease (ESRD) program and Chronic Kidney Disease (CKD)
S.870, CHRONIC Care Act of 2017
SNP reauthorization
H.R. 2644/S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017
Medicare extenders package
H.R. 3178, Medicare Part B Improvement Act of 2017
Issues related to healthcare discussions/offsets for budget deal and healthcare extender policies
H.R. 1892 / PL 115-123, Bipartisan Budget Act of 2018
H.R. 1625 / PL 115-141, Omnibus/Consolidated Appropriations Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2017
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Feb. 20, 2018.
Original Filing: 300940529.xml
Lobbying Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules; ESRD prospective payment system CY 2017; Quality Incentive Program PY 2020 Final Rule; CMS proposed updates to policies and payment rates for end-stage renal disease prospective payment system, quality incentive program, and payment for renal dialysis services furnished to individuals with acute kidney injury (CMS 1674-P); Issues related to survey and certification of dialysis facilities under sub-regulatory guidance issued by the CMS Centers for Clinical Standards and Quality, Survey and Certification Group; Issues related to charitable premium assistance for individuals with ESRD; H.R. 3976, the Protecting Access to Marketplace Insurance Act of 2017; H.R. 5942, the PATIENTs Act (114th Congress); S. 870, the CHRONIC Act of 2017; H.R. 3178, the Medicare Part B Improvement Act (includes H.R. 3166, dialysis factility accreditation legislation) of 2017; H.R. 2644, CKD Improvement in Research and Treatment Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
3rd Quarter, 2017
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Oct. 20, 2017.
Original Filing: 300912040.xml
Lobbying Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules; ESRD prospective payment system CY 2017; Quality Incentive Program PY 2020 Final Rule; CMS proposed updates to policies and payment rates for end-stage renal disease prospective payment system, quality incentive program, and payment for renal dialysis services furnished to individuals with acute kidney injury (CMS 1674-P); Issues related to survey and certification of dialysis facilities under sub-regulatory guidance issued by the CMS Centers for Clinical Standards and Quality, Survey and Certification Group; Issues related to charitable premium assistance for individuals with ESRD; H.R. 3976, the Protecting Access to Marketplace Insurance Act of 2017; H.R. 5942, the PATIENTs Act (114th Congress); S. 870, the CHRONIC Act of 2017; H.R. 3178, the Medicare Part B Improvement Act (includes H.R. 3166, dialysis factility accreditation legislation) of 2017; H.R. 2644, CKD Improvement in Research and Treatment Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
2nd Quarter, 2017
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300892109.xml
Lobbying Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules; ESRD prospective payment system CY 2017; Quality Incentive Program PY 2020 Final Rule
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
1st Quarter, 2017
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300872801.xml
Lobbying Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
4th Quarter, 2016
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Jan. 19, 2017.
Original Filing: 300851055.xml
Lobbying Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
3rd Quarter, 2016
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Oct. 20, 2016.
Original Filing: 300839529.xml
Lobbying Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development); The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); The Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; The Dialysis PATIENT Act (S. 3090, H.R. 5506); The ERSD Choice Act (H.R. 5659); Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
2nd Quarter, 2016
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on July 18, 2016.
Original Filing: 300812350.xml
Lobbying Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Contacted the Center for Consumer Information & Insurance Oversight (CCIIO) relating to Exchange function for individuals with ERSD; The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
1st Quarter, 2016
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on April 19, 2016.
Original Filing: 300795405.xml
Lobbying Issues
Implementation of the Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Contacted the Center for Consumer Information & Insurance Oversight (CCIIO) relating to Exchange function for individuals with ERSD; The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); the Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 1458); HHS Notice of Benefit and Payment Parameters for 2017, Final 2017 Letter to Issuers in the Federally-facilitated Marketplaces; Issues related to ERSD Program; S. 598 and H.R. 1130, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Medicare Advantage; Senate Finance Committee Chronic Care Working Group; Integrated care legislation; Access to coverage in Health Insurance Marketplaces for ESRD; Implementation of Pub. L. 114-27, the Trade Preferences Extension Act of 2015; OCR anti-discrimination proposed and final rules; ERSD quality programs; ERSD payment rules.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
4th Quarter, 2015
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Jan. 20, 2016.
Original Filing: 300779507.xml
Lobbying Issues
Implementation of P.L. 113-93, the Protecting Access to Medicare Act of 2014; The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Issues related to chronic care; Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; physician fee schedule rule; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Contacted the Center for Consumer Information & Insurance Oversight (CCIIO) relating to Exchange function for individuals with ERSD; ERSD quality programs; ERSD Five Star initiative; The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015 and policy issues related to ERSD; HHS Notice of Benefit and Payment Parameters for 2016, Final 2016 Letter to Issuers in the Federally-facilitated Marketplaces; and Medicare Advantage and policy issues related to ERSD; H.R. 1130 and S. 598, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Implementation of P.L. 114-27, the Trade Preferences Extension Act of 2015; H.R. 6, the 21st Century Cures Act; issues related to risk adjustment; issues related to data transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
3rd Quarter, 2015
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Oct. 20, 2015.
Original Filing: 300764039.xml
Lobbying Issues
Implementation of P.L. 113-93, the Protecting Access to Medicare Act of 2014; The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Issues related to chronic care; Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; physician fee schedule rule; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Contacted the Center for Consumer Information & Insurance Oversight (CCIIO) relating to Exchange function for individuals with ERSD; ERSD quality programs; ERSD Five Star initiative; The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015 and policy issues related to ERSD; HHS Notice of Benefit and Payment Parameters for 2016, Final 2016 Letter to Issuers in the Federally-facilitated Marketplaces; and Medicare Advantage and policy issues related to ERSD; H.R. 1130 and S. 598, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Implementation of P.L. 114-27, the Trade Preferences Extension Act of 2015; H.R. 6, the 21st Century Cures Act; issues related to risk adjustment; issues related to data transparency.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
2nd Quarter, 2015
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on July 20, 2015.
Original Filing: 300743621.xml
Lobbying Issues
Implementation of P.L. 113-93, the Protecting Access to Medicare Act of 2014; The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; physician fee schedule rule; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Contacted the Center for Consumer Information & Insurance Oversight (CCIIO) relating to Exchange function for individuals with ERSD; ERSD quality programs; ERSD Five Star initiative; The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); Medicare and State Health Care Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute; and Civil Monetary Penalty Rules Regarding Beneficiary Inducements and Gainsharing: Proposed Rule, 79 Fed. Reg. 59717 (Oct. 3, 2014); H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015 and policy issues related to ERSD; HHS Notice of Benefit and Payment Parameters for 2016, Final 2016 Letter to Issuers in the Federally-facilitated Marketplaces; and Medicare Advantage and policy issues related to ERSD; H.R. 1130 and S. 598, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Implementation of P.L. 114-27, the Trade Preferences Extension Act of 2015.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Implementation of P.L. 113-93, the Protecting Access to Medicare Act of 2014; The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; physician fee schedule rule; Centers for Medicare & Medicaid Services, Letter to Issuers on federally-facilitated Marketplace(Issues related to Marketplace Development), 4 February 2014; Contacted the Center for Consumer Information & Insurance Oversight (CCIIO) relating to Exchange function for individuals with ERSD; ERSD quality programs; ERSD Five Star initiative; The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); Medicare and State Health Care Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute; and Civil Monetary Penalty Rules Regarding Beneficiary Inducements and Gainsharing: Proposed Rule, 79 Fed. Reg. 59717 (Oct. 3, 2014); H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015 and policy issues related to ERSD; HHS Notice of Benefit and Payment Parameters for 2016, Final 2016 Letter to Issuers in the Federally-facilitated Marketplaces; and Medicare Advantage and policy issues related to ERSD; H.R. 1130 and S. 598, the Chronic Kidney Disease Improvement in Research and Treatment Act of 2015; Implementation of P.L. 114-27, the Trade Preferences Extension Act of 2015.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2015
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on April 20, 2015.
Original Filing: 300725499.xml
Lobbying Issues
The Protecting Access to Medicare Act of 2014 (Pub. L. 113-93); The Budget Control Act of 2011 (Pub. L. 112-25); Implementation of the Patient Protection and Affordable Care Act (Pub. L. 111-148); The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); The American Taxpayer Relief Act of 2012 (Pub. L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; physician fee schedule rule; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Contacted the Center for Consumer Information & Insurance Oversight (CCIIO) relating to Exchange function for individuals with ERSD; ERSD quality programs; ERSD Five Start initiative; The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); Medicare and State Health Care Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute; and Civil Monetary Penalty Rules Regarding Beneficiary Inducements and Gainsharing: Proposed Rule, 79 Fed. Reg. 59717 (Oct. 3, 2014); H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015 and policy issues related to ERSD; HHS Notice of Benefit and Payment Parameters for 2016, Final 2016 Letter to Issuers in the Federally-facilitated Marketplaces; and Medicare Advantage and policy issues related to ERSD.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
4th Quarter, 2014
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Jan. 20, 2015.
Original Filing: 300704305.xml
Lobbying Issues
Protecting Access to Medicare Act of 2014 (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare &Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Comprehensive ESRD Care Initiative; Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; physician fee schedule; ESRD quality programs; ESRD Dialysis Facility Compare and Five Star initiative; H.R. 4814 Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies;Proposed Rule [CMS-1614-P]; Exchange function for individuals with ESRD; The Achieving a Better Life Experience Act of 2014 (ABLE Act of 2014); Medicare and state health care programs: fraud and abuse; revisions to Safe Harbors under the Anti-Kickback Statute; Civil Monetary Penalty Rules Regarding Beneficiary Inducements and Gainsharing: Proposed Rule, 79 Fed. Reg. 59717 (Oct.3, 2014). Also contacted the Center for Consumer Information & Insurance Oversight (CCIIO).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
3rd Quarter, 2014
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Oct. 20, 2014.
Original Filing: 300689219.xml
Lobbying Issues
Protecting Access to Medicare Act of 2014 (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Comprehensive ESRD Care Initiative; Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; physician fee schedule; ESRD quality programs; ESRD Dialysis Facility Compare and Five Star initiative; H.R. 4814 Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Proposed Rule [CMS-1614-P].
Also contacted the Center for Consumer Information & Insurance Oversight (CCIIO).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
2nd Quarter, 2014
THE KIDNEY CARE COUNCIL amended a lobbying report for in-house lobbying in Q22014 on Oct. 20, 2014
Original Filing: 300689203.xml
Lobbying Issues
Protecting Access to Medicare Act of 2014" (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Comprehensive ESRD Care Initiative; Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; physician fee schedule.
Also contacted the Center for Consumer Information & Insurance Oversight (CCIIO).
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
2nd Quarter, 2014
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on July 21, 2014.
Original Filing: 300669150.xml
Lobbying Issues
Protecting Access to Medicare Act of 2014 (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Comprehensive ESRD Care Initiative; Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; physician fee schedule.
Also contacted the Center for Consumer Information & Insurance Oversight (CCIIO).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
Protecting Access to Medicare Act of 2014 (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment
System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F];CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014; Comprehensive ESRD Care Initiative; Chronic Kidney Disease Improvement in Research and Treatment Act of 2014; physician fee schedule.
Also contacted the Center for Consumer Information & Insurance Oversight (CCIIO).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
1st Quarter, 2014
THE KIDNEY CARE COUNCIL amended a lobbying report for in-house lobbying in Q12014 on Oct. 20, 2014
Original Filing: 300689177.xml
Lobbying Issues
Protecting Access to Medicare Act of 2014 (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014.
Also contacted the Center for Consumer Information & Insurance Oversight.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Health Issues Medicare/Medicaid
1st Quarter, 2014
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on April 21, 2014.
Original Filing: 300648442.xml
Lobbying Issues
Protecting Access to Medicare Act of 2014 (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F]; CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014.
Also contacted the Center for Consumer Information & Insurance Oversight (CCIIO).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
Protecting Access to Medicare Act of 2014 (Public Law No. 113.93); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240); Medicare Program; End-Stage Renal Disease Prospective Payment
System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule [CMS-1526-F];CMS Transmittal 171, CR 8271 Revisions to Medicare Benefit Policy Manual; Centers for Medicare & Medicaid Services, Letter to Issuers on Federally-facilitated Marketplace (Issues related to Marketplace Development), 4 February 2014.
Also contacted the Center for Consumer Information & Insurance Oversight (CCIIO).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
4th Quarter, 2013
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Jan. 21, 2014.
Original Filing: 300626451.xml
Lobbying Issues
Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Bad Debt Reductions for All Medicare Providers; Proposed Rule [CMS CMS-1352-P]; The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Type of Issue
Health Issues Medicare/Medicaid
3rd Quarter, 2013
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Oct. 21, 2013.
Original Filing: 300606276.xml
Lobbying Issues
Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Bad Debt Reductions for All Medicare Providers; Proposed Rule [CMS CMS-1352-P]; The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Type of Issue
Health Issues Medicare/Medicaid
2nd Quarter, 2013
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on July 22, 2013.
Original Filing: 300585094.xml
Lobbying Issues
The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Type of Issue
Health Issues Medicare/Medicaid
1st Quarter, 2013
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on April 22, 2013.
Original Filing: 300563907.xml
Lobbying Issues
CY 2013 End-Stage Renal Disease Prospective Payment System Final Rule (CMS-1352-F); the Patient Protection and Affordable Care Act; Standards Related to Essential Health Benefits, Actuarial Equivalence, and Accreditation (77 Fed. Reg. 70,644); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240).Medicare Program: Comprehensive End-Stage Renal Disease Care Model Announcement (CMS-5506-N).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Type of Issue
Health Issues Medicare/Medicaid
4th Quarter, 2012
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Jan. 22, 2013.
Original Filing: 300539842.xml
Lobbying Issues
CY 2013 End-Stage Renal Disease Prospective Payment System Final Rule (CMS-1352-F); the Patient Protection and Affordable Care Act; Standards Related to Essential Health Benefits, Actuarial Equivalence, and Accreditation (77 Fed. Reg. 70,644); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); The American Taxpayer Relief Act of 2012 (P.L. 112-240).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Type of Issue
Health Issues Medicare/Medicaid
3rd Quarter, 2012
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Oct. 22, 2012.
Original Filing: 300520305.xml
Lobbying Issues
HHS Final Rule on Exchange Establishment ([CMS9989F]; IRS/Treasury final rule on health insure premium credit (RIN 1545BJ82); Proposed CY 2013 End-Stage Renal Disease Prospective Payment System (CMS-1352-P); The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Type of Issue
Health Issues Medicare/Medicaid
2nd Quarter, 2012
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on July 20, 2012.
Original Filing: 300496698.xml
Lobbying Issues
CMS-6037-P: Medicare Program; Reporting and Returning of Overpayments: Proposed Rule; The Budget Control Act of 2011 (Pub.L. 112-25); The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); Issues related to the ESRD Quality Incentive Program (QIP).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Type of Issue
Health Issues Medicare/Medicaid
1st Quarter, 2012
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on April 19, 2012.
Original Filing: 300468482.xml
Lobbying Issues
Essential Health Benefits Bulletin, released by the Consumer Information and Insurance Oversight (CCIIO) on December 16, 2011; The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
CMS-9070-P: Medicare and Medicaid Program; Regulatory Provisions to Promote Program Efficiency, Transparency, and Burden Reduction: Proposed Rule; Agency Information Collection: Independent Renal Dialysis Facility Cost Report; Document Identifier CMS-265-11 (Notice); Health Insurance Premium Tax Credit Regulation (REG 131491-10); Patient Protection and Affordable Care Act; Establishment of Exchanges and Qualified Health Plans; Proposed rule [CMS-9989-P].
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
4th Quarter, 2011
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Jan. 20, 2012.
Original Filing: 300451428.xml
Lobbying Issues
CMS-9070-P: Medicare and Medicaid Program; Regulatory Provisions to Promote Program Efficiency, Transparency, and Burden Reduction: Proposed Rule; Agency Information Collection: Independent Renal Dialysis Facility Cost Report; Document Identifier CMS-265-11 (Notice); Health Insurance Premium Tax Credit Regulation (REG 131491-10); Patient Protection and Affordable Care Act; Establishment of Exchanges and Qualified Health Plans; Proposed rule [CMS-9989-P].
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Type of Issue
Health Issues Medicare/Medicaid
3rd Quarter, 2011
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Oct. 20, 2011.
Original Filing: 300429237.xml
Lobbying Issues
The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); Changes to the ESRD Prospective Payment System Transition Budget Neutrality Adjustment (CMS-1435-IFC); Request for Comments Regarding Exchange-Related Provisions in Title 1 of the Patient Protection and Affordable Care Act (OCIIO-99890NC); (CSM-1345-NC); Institute of Medicine, Consensus Study, Determination of Essential Health Benefits;End-Stage Renal Disease Quality Incentive Program for PY 2013 and PY 2014; Proposed Rule (CMS-1577-P); Establishment of Exchanges and Qualified Health Plans, and Standards Related to Reinsurance, Risk Corridors and Risk Adjustment; Extension of Comment Period [CMS-9989-N2]; Exchange Functions in the Individual Market: Eligibility Determinations; Exchange Standards for Employers: Proposed Rule [CMS-9974-P]; Health Insurance Premium Tax Credits: Proposed Rule (REG-131491-10).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Type of Issue
Health Issues Medicare/Medicaid
2nd Quarter, 2011
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on July 19, 2011.
Original Filing: 300398732.xml
Lobbying Issues
The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); Changes to the ESRD Prospective Payment System Transition Budget Neutrality Adjustment (CMS-1435-IFC); Request for Comments Regarding Exchange-Related Provisions in Title 1 of the Patient Protection and Affordable Care Act (OCIIO-99890NC); (CSM-1345-NC); Institute of Medicine, Consensus Study, Determination of Essential Health Benefits.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); Medicare Program; End-Stage Renal Disease Prospective Payment System; Final Rule and Proposed Rule (CMS-1418-F); Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for Cy 2011 Proposed Rule (CMS-1503-P)
Request for Comments Regarding Exchange-Related Provisions in Title 1 of the Patient Protection and Affordable Care Act (OCIIO-99890NC); (CSM-1345-NC); Institute of Medicine, Consensus Study, Determination of Essential Health Benefits.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
1st Quarter, 2011
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on April 20, 2011.
Original Filing: 300379418.xml
Lobbying Issues
The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); Changes to the ESRD Prospective Payment System Transition Budget Neutrality Adjustment (CMS-1435-IFC); Request for Comments Regarding Exchange-Related Provisions in Title 1 of the Patient Protection and Affordable Care Act (OCIIO-99890NC); Medicare Program, Request for Information Regarding Accountable Care Organizations and the Medicare Shared Savings Program (CSM-1345-NC); Institute of Medicine, Consensus Study, Determination of Essential Health Benefits.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); Medicare Program; End-Stage Renal Disease Prospective Payment System; Final Rule and Proposed Rule (CMS-1418-F); Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for Cy 2011 Proposed Rule (CMS-1503-P)
Request for Comments Regarding Exchange-Related Provisions in Title I of the Patient Protection Affordable Care Act (OCIIO-9989-NC); Medicare Program, Request for Information Regarding Accountable Care Organizations and the Medicare Shared Savings Program (CMS-1345-NC); Institute of Medicine, Consensus Study, Determination of Essential Health Benefits"
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
4th Quarter, 2010
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Jan. 20, 2011.
Original Filing: 300354402.xml
Lobbying Issues
The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); Medicare Program, End-Stage Renal Disease Prospective Payment System; Final Rule and Proposed Rule (CMS-1418-F); -Medicare Program, Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2011 Proposed Rule (CMS-1503-P); Planning and Establishment of State-Level Exchanges; Request for Comments Regarding Exchange-Related Provisions in Title I of the Patient Protection and Affordable Care Act (OCIIO-9989-NC); Medicare Program, Request for Information Regarding Accountable Care Organizations and the Medicare Shared Savings Program (CMS-1345-NC); Institute of Medicine, Consensus Study, Determination of Essential Health Benefits.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Veterans Affairs - Dept of (VA)
3rd Quarter, 2010
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Oct. 20, 2010.
Original Filing: 300325777.xml
Lobbying Issues
The Patient Protection and Affordable Care Act (P.L. 111-148); The Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); Medicare Program; End-Stage Renal Disease Prospective Payment System; Proposed Rule (CMS-1418-P); Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2011 Proposed Rule (CMS-1503-P).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Veterans Affairs - Dept of (VA)
2nd Quarter, 2010
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on July 20, 2010.
Original Filing: 300299199.xml
Lobbying Issues
PL 111-148 Patient Protection and Affordable Care Act; PL 111-152 Health Care and Education Reconciliation Act of 2010; Medicare Program; End-Stage Renal Disease Prospective Payment System; Proposed Rule (CMS-1418-P); Dep't of Veterans Affairs "Payment for Inpatient and Outpatient Health Care Professional Services at Non-Departmental Facilities and Other Medical Charges Associated with Non-VA Outpatient Care" (38 CFR part 17, RIN 2900-AN37.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Veterans Affairs - Dept of (VA)
1st Quarter, 2010
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on April 20, 2010.
Original Filing: 300273553.xml
Lobbying Issues
Senate Health Reform Bill - Patient Protection and Affordable Care Act (H.R. 3590); House Health Reform Bill -
Affordable Health Care for America Act (H.R. 3962); Patient Protection and Affordable Care Act (P.L. 111-148); Health Care and Education Reconciliation Act of 2010 (P.L. 111-152); Medicare Program; End-Stage Renal Disease Prospective Payment System; Proposed Rule (CMS-1418-P)RIN 2900-AN37Payment for Inpatient and Outpatient Health Care Professional Services at Non-Departmental Facilities and Medical Charges Associated with Non-VA Outpatient Care
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Veterans Affairs - Dept of (VA)
4th Quarter, 2009
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Jan. 20, 2010.
Original Filing: 300247239.xml
Lobbying Issues
America's Affordable Health Choices Act of 2009 (HR 3200); Affordable Health Choices Act (S. 1679); House Tri-
Committee and Senate Finance Health Reform Proposals; Medicare Program: End-Stage Renal Disease Prospective
Payment System: Proposed Rule ("CMS-1418-P"); Medicare Program; Payment Policies Under the Physician Fee
Schedule and Other Revisions to Part B for CY 2010; Proposed Rule ("CMS-1413-P")
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Treasury - Dept of
3rd Quarter, 2009
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Oct. 20, 2009.
Original Filing: 300219207.xml
Lobbying Issues
America's Affordable Health Choices Act of 2009 (HR 3200); Affordable Health Choices Act (S. 1679); House Tri-Committee and Senate Finance Health Reform Proposals; Medicare Program: End-Stage Renal Disease Prospective Payment System: Proposed Rule ("CMS-1418-P"); Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2010; Proposed Rule ("CMS-1413-P")
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Treasury - Dept of
2nd Quarter, 2009
In Q2, THE KIDNEY CARE COUNCIL did no lobbying for itself. The report was filed on July 21, 2009.
Original Filing: 300194623.xml
1st Quarter, 2009
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on March 23, 2009.
Original Filing: 300141399.xml
Lobbying Issues
Regulatory work with CMS on implementation of H.R. 6331, The Medicare Improvements for Patients and Providers Act of 2008. Worked with the House and Senate on the economic stimilus bill on matters involving Survey and Certification of new Medicare facilities.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
1st Quarter, 2009
THE KIDNEY CARE COUNCIL amended a lobbying report for in-house lobbying in Q12009 on March 23, 2009
Original Filing: 300141408.xml
Lobbying Issues
Regulatory work with CMS on implementation of H.R. 6331, The Medicare Improvements for Patients and Providers Act of 2008. Worked with the House and Senate on the economic stimilus bill on matters involving Survey and Certification of new Medicare facilities.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
4th Quarter, 2008
THE KIDNEY CARE COUNCIL amended a lobbying report for in-house lobbying in Q42008 on March 31, 2009
Original Filing: 300142493.xml
Lobbying Issues
H.R. 6331, The Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office
4th Quarter, 2008
In Q4, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Jan. 16, 2009.
Original Filing: 300122610.xml
Lobbying Issues
H.R. 6331, The Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office
3rd Quarter, 2008
In Q3, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on Oct. 15, 2008.
Original Filing: 300093294.xml
Lobbying Issues
S. 691, the Kidney Care Quality and Education Act of 2008 relating to Medicare reimbursement under the End Stage Renal Disease Program; and H.R. 6331, the Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office
2nd Quarter, 2008
In Q2, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on July 17, 2008.
Original Filing: 300070422.xml
Lobbying Issues
S.691, The Kidney Care Quality and Education Act relating to Medicare reimbursement under the End Stage Renal Disease Program; and H.R. 6331, the Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) White House Office
1st Quarter, 2008
In Q1, THE KIDNEY CARE COUNCIL had in-house lobbyists. The report was filed on April 21, 2008.
Original Filing: 300051611.xml
Lobbying Issues
S. 691, the Kidney Care Quality and Education Act relating to Medicare reimbursement under the End Stage Renal Disease Program.
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) White House Office Health & Human Services - Dept of (HHS) U.S. House of Representatives U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate